Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Feb 5;108(2):461-8.
doi: 10.1038/bjc.2012.486. Epub 2012 Nov 13.

An inherited NBN mutation is associated with poor prognosis prostate cancer

C Cybulski  1 , D Wokołorczyk, W Kluźniak, A Jakubowska, B Górski, J Gronwald, T Huzarski, A Kashyap, T Byrski, T Dębniak, A Gołąb, B Gliniewicz, A Sikorski, J Switała, T Borkowski, A Borkowski, A Antczak, L Wojnar, J Przybyła, M Sosnowski, B Małkiewicz, R Zdrojowy, P Sikorska-Radek, J Matych, J Wilkosz, W Różański, J Kiś, K Bar, P Bryniarski, A Paradysz, K Jersak, J Niemirowicz, P Słupski, P Jarzemski, M Skrzypczyk, J Dobruch, P Domagała, S A Narod, J Lubiński; Polish Hereditary Prostate Cancer Consortium
Collaborators, Affiliations

An inherited NBN mutation is associated with poor prognosis prostate cancer

C Cybulski et al. Br J Cancer. .

Abstract

Background: To establish the contribution of eight founder alleles in three DNA damage repair genes (BRCA1, CHEK2 and NBS1) to prostate cancer in Poland, and to measure the impact of these variants on survival among patients.

Methods: Three thousand seven hundred fifty men with prostate cancer and 3956 cancer-free controls were genotyped for three founder alleles in BRCA1 (5382insC, 4153delA, C61G), four alleles in CHEK2 (1100delC, IVS2+1G>A, del5395, I157T), and one allele in NBS1 (657del5).

Results: The NBS1 mutation was detected in 53 of 3750 unselected cases compared with 23 of 3956 (0.6%) controls (odds ratio (OR)=2.5; P=0.0003). A CHEK2 mutation was seen in 383 (10.2%) unselected cases and in 228 (5.8%) controls (OR=1.9; P<0.0001). Mutation of BRCA1 (three mutations combined) was not associated with the risk of prostate cancer (OR=0.9; P=0.8). In a subgroup analysis, the 4153delA mutation was associated with early-onset (age ≤ 60 years) prostate cancer (OR=20.3, P=0.004). The mean follow-up was 54 months. Mortality was significantly worse for carriers of a NBS1 mutation than for non-carriers (HR=1.85; P=0.008). The 5-year survival for men with an NBS1 mutation was 49%, compared with 72% for mutation-negative cases.

Conclusion: A mutation in NBS1 predisposes to aggressive prostate cancer. These data are relevant to the prospect of adapting personalised medicine to prostate cancer prevention and treatment.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Kaplan–Meier curves of prostate cancer patients with: (A) mutation in NSB1 (n=52); (B) mutation in BRCA1 (n=13); (C) mutation in CHEK2 (n=340), compared with prostate cancer patients with no mutation (non-carriers; n=3082).
See this image and copyright information in PMC

References

    1. Brennan P, McKay J, Moore L, Zaridze D, Mukeria A, Szeszenia-Dabrowska N, Lissowska J, Rudnai P, Fabianova E, Mates D, Bencko V, Foretova L, Janout V, Chow WH, Rothman N, Chabrier A, Gaborieau V, Odefrey F, Southey M, Hashibe M, Hall J, Boffetta P, Peto J, Peto R, Hung RJ. Uncommon CHEK2 missense variant and reduced risk of tobacco-related cancers: Case control study. Hum Mol Genet. 2007;16:1794–1801. - PubMed
    1. Chrzanowska KH, Piekutowska-Abramczuk D, Popowska E, Gładkowska-Dura M, Małdyk J, Syczewska M, Krajewska-Walasek M, Goryluk-Kozakiewicz B, Bubała H, Gadomski A, Gaworczyk A, Kazanowska B, Kołtan A, Kuźmicz M, Luszawska-Kutrzeba T, Maciejka-Kapuścińska L, Stolarska M, Stefańska K, Sznurkowska K, Wakulińska A, Wieczorek M, Szczepański T, Kowalczyk J. Carrier frequency of mutation 657del5 in the NBS1 gene in a population of Polish pediatric patients with sporadic lymphoid malignancies. Int J Cancer. 2006;118:1269–1274. - PubMed
    1. Cybulski C, Górski B, Debniak T, Gliniewicz B, Mierzejewski M, Masojć B, Jakubowska A, Matyjasik J, Złowocka E, Sikorski A, Narod SA, Lubiński J. NBS1 is a prostate cancer susceptibility gene. Cancer Res. 2004;64:1215–1219. - PubMed
    1. Cybulski C, Wokołorczyk D, Huzarski T, Byrski T, Gronwald J, Górski B, Debniak T, Masojć B, Jakubowska A, Gliniewicz B, Sikorski A, Stawicka M, Godlewski D, Kwias Z, Antczak A, Krajka K, Lauer W, Sosnowski M, Sikorska-Radek P, Bar K, Klijer R, Zdrojowy R, Małkiewicz B, Borkowski A, Borkowski T, Szwiec M, Narod SA, Lubiński J. A large germline deletion in the Chek2 kinase gene is associated with an increased risk of prostate cancer. J Med Genet. 2006;43:863–866. - PMC - PubMed
    1. Cybulski C, Wokołorczyk D, Jakubowska A, Huzarski T, Byrski T, Gronwald J, Masojć B, Debniak T, Górski B, Blecharz P, Narod SA, Lubiński J. Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer. J Clin Oncol. 2011;29:3747–3752. - PubMed

Publication types